UPCC 28218: A Phase II Study of Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors
Brief description of study
This is a single-arm phase II study of twenty-one subjects with mucinous adenocarcinoma of the colon, rectum, or appendix with prior systemic therapy with a fluoropyrimidine, oxaliplatin, and irinotecan. Treatment will consist of nivolumab every 4 weeks and ipilimumab every 8 weeks until disease progression, unacceptable toxicity, or 2 years of therapy.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Colorectal cancer
-
Age: - 99 Years
-
Gender: All
Updated on
29 Jan 2020.
Study ID: 831705